Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50%

Core Viewpoint - Novo Nordisk plans to reduce the list prices of its diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50% in the U.S. starting January 1, 2027, coinciding with new lower prices under Medicare plans [1][2]. Pricing Changes - The new list price for Ozempic and Wegovy will be set at $675, reflecting a 50% reduction for Wegovy and a 35% reduction for Ozempic from current prices [2]. - The price cuts will also apply to Wegovy and Rybelsus pills, enhancing accessibility for patients [2]. Market Opportunity - The decision to lower prices aims to address the needs of over 100 million individuals living with obesity and more than 35 million with type 2 diabetes in the U.S. [3]. - The lower list prices are intended to eliminate cost barriers, particularly for patients with high-deductible health plans or co-insurance designs [6]. Competitive Landscape - The GLP-1 drug market is becoming increasingly competitive, with Novo Nordisk's Wegovy being sold directly to consumers for $349, significantly lower than the official list price [11]. - Novo Nordisk and Eli Lilly have entered agreements with the U.S. government to reduce prices and sell products through a government website, enhancing their market presence [12]. Regulatory Approvals - Ozempic is FDA-approved for type 2 diabetes and chronic kidney disease, while both Ozempic and Wegovy are approved for comorbid cardiovascular disease [8].